Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies

BH3 mimetics are novel targeted drugs with remarkable specificity, potency and enormous potential to improve cancer therapy. However, acquired resistance is an emerging problem. We report the rapid development of resistance in chronic lymphocytic leukemia cells isolated from patients exposed to incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Zebeeby, Aoula, Vogler, Meike, Milani, Mateus, Richards, Caitlin, Alotibi, Ahoud, Greaves, Georgia, Dyer, Martin J.S., Cohen, Gerald M., Varadarajan, Shankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518917/
https://www.ncbi.nlm.nih.gov/pubmed/30467206
http://dx.doi.org/10.3324/haematol.2018.204701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518917/
https://www.ncbi.nlm.nih.gov/pubmed/30467206
http://dx.doi.org/10.3324/haematol.2018.204701

Ejemplares similares